Science
Leading the World in AI Drug Development
To develop new drugs, we must first understand the interactions between disease-associated Proteins.
Protein to Protein Interaction
Normal physiological reactions and disease-associated pathological reactions
require certain specific protein interactions to perform.
The development of new drugs and new diagnostic reagents must first
understand the interaction between those related proteins.
Industry Pain Points of New Drug Development
Contemporary methods are inefficient for studying protein-protein interactions (PPI).
Unable to
synthesize/purify
Some key proteins cannot
be synthesized or purified in
good enough quantity in
vitro for functional studies.
Unknown PPI
Humans have more than
20,000 proteins, and it is
difficult to find which
proteins interact with each
other. Without this information,
it is impossible to
design suitable new drugs.
Unknown
structures
Detailed 3D structures of
protein interactions are
lacking.
Long lead time &
high expenses
Only preliminary results
take years and are
expensive; experimental
results are often
inconsistent and failure
rates are high.
Our Solutions : AgnistaAI Platform
AgnistaAI has made a leap in the field of high-throughput exploration of protein functions, achieving rapid and safe drug innovation.
Novel Antibody
Design highly developable natively paired antibodies against proteins that cannot be purified.
High Throughput
Can conduct a large scale of rapid screenings among >20,000 proteins to find those proteins (ex. Enzyme) that can regulate a specific protein receptor.
Accelerating Design
Swiftly find the molecular mechanism of protein interactions that could not be discovered before and accelerate the design of new drugs and diagnostic reagents.
R&D efficiency
Provide unprecedented predictability and developability of preclinical drug safety. Reduce the initial drug discovery time by at least 90%.
Technology Highlights
Making Impossible Possible
High Throughput Screening
The only platform that can screen interacting proteins in large quantities to accelerate the R&D of new drugs.
Short Lead Time &
Low Cost
Discover new natively paired antibodies in less than 1/10 time and 1/2 the cost.
PPI
Determining the 3D structure of PPIs take less than 1/10 the time and 1/6 the cost.
No Purification
New therapeutic or diagnostic antibodies can be designed without the need for purified target proteins.
Verify Safety Profile at High Speed
The only platform that can verify the safety of new biological drugs before clinical use.
Successful Rates +
Can increase successful
rates of R&D new drugs.
High Throughput
Screening
The only platform that can
screen interacting proteins in
large quantities to accelerate
the R&D of new drugs.
Short Lead Time &
Low Cost
Discover new natural
paired antibodies in 1/10
time and 1/2 the cost.
PPI
Determining the 3D
structure of PPIs take
less than 1/10 the time
and 1/6 the cost.
No Purification
New therapeutic or
diagnostic antibodies can be
designed without the need
for purified target proteins.
Verify Safety Profile
at High Speed
The only platform that can
verify the safety of new
biological drugs before
clinical use.